METABOLIC PROFILING OF NON-METASTATIC AS COMPARED TO METASTATIC RENAL CELL CARCINOMAS
Carsten Kempkensteffen(Charité - Universitätsmedizin Berlin), Steffen Weikert(St. Hedwig-Krankenhaus), Stefan Hinz(Charité - Universitätsmedizin Berlin), Gareth Catchpole(Max Planck Institute of Molecular Plant Physiology), Frank Christoph(Charité - Universitätsmedizin Berlin), Lothar Willmitzer(Max Planck Society), Kurt Miller(Charité - Universitätsmedizin Berlin), Alexander Platzer(University of Potsdam), Joachim Selbig(Max Planck Society)
Cited by 0
Related Papers
Enzalutamide in Metastatic Prostate Cancer before Chemotherapy
|New England Journal of Medicine|2014|3k
Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naive men with metastatic castration-resistant prostate cancer (COU-AA-302): final overall survival analysis of a randomised, double-blind, placebo-controlled phase 3 study
|The Lancet Oncology|2015|1.4k
The Epidemiology of Renal Cell Carcinoma
|European Urology|2011|1k
Enzalutamide in Men with Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer: Extended Analysis of the Phase 3 PREVAIL Study
|European Urology|2016|414
PhosPhAt: a database of phosphorylation sites in Arabidopsis thaliana and a plant-specific phosphorylation site predictor
|Nucleic Acids Research|2007|355